Lene Kongsgaard Nielsen - JoVE Visualize

Showing results (11-20 of 25) with videos related to

Pageof 3

Sort By:

The Lancet. Haematology|February 5, 2025

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trialFrida Bugge Askeland, Einar Haukås, Tobias S Slørdahl, et al.

Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 2, 2021

Implications of response shift for micro-, meso-, and macro-level healthcare decision-making using results of patient-reported outcome measuresRichard Sawatzky, Jae-Yung Kwon, Ruth Barclay, et al.

Journal of Patient-Reported Outcomes|April 29, 2025

Translation, cultural adaptation and validation of the Danish version of the haematological malignancy patient-reported outcome measure (HM-PRO)Sam Salek, Sören Möller, Niels Abildgaard, et al.

Journal of Multimorbidity and Comorbidity|February 2, 2026

Association of the Tilburg Frailty Indicator with mortality, readmission, and healthcare contacts in adult patients with multimorbidityThomas J Hjelholt, Thomas Veedfald, Anne Frølich, et al.

Experimental Hematology & Oncology|August 21, 2018

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myelomaHenrik Gregersen, Trung Do, Ida Bruun Kristensen, et al.

European Journal of Haematology|September 20, 2018

Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patientsLene Kongsgaard Nielsen, Tobias Wirenfeldt Klausen, Mary Jarden, et al.

Leukemia & Lymphoma|March 25, 2026

First-line immunochemotherapy for indolent lymphoma does not affect muscle volume: a post hoc analysis of 472 patients in long-term remissions from the GALLIUM studyJennifer Bøgh Jørgensen, Kim Vang Hansen, Lene Kongsgaard Nielsen, et al.

Leukemia|August 11, 2023

Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantationJakob Nordberg Nørgaard, Niels Abildgaard, Anna Lysén, et al.

Health and Quality of Life Outcomes|November 5, 2021

Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational studyMia Sommer, Lene Kongsgaard Nielsen, Lars Børty Nielsen, et al.

Archives of Gerontology and Geriatrics|January 21, 2021

Clinical presentation and mortality in hospitalized patients aged 80+ years with COVID-19-A retrospective cohort studyLinda Katharina Karlsson, Lasse Hjort Jakobsen, Louise Hollensberg, et al.

Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:

Pageof 3

The Lancet. Haematology|February 5, 2025

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trialFrida Bugge Askeland, Einar Haukås, Tobias S Slørdahl, et al.

Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 2, 2021

Implications of response shift for micro-, meso-, and macro-level healthcare decision-making using results of patient-reported outcome measuresRichard Sawatzky, Jae-Yung Kwon, Ruth Barclay, et al.

Journal of Patient-Reported Outcomes|April 29, 2025

Translation, cultural adaptation and validation of the Danish version of the haematological malignancy patient-reported outcome measure (HM-PRO)Sam Salek, Sören Möller, Niels Abildgaard, et al.

Journal of Multimorbidity and Comorbidity|February 2, 2026

Association of the Tilburg Frailty Indicator with mortality, readmission, and healthcare contacts in adult patients with multimorbidityThomas J Hjelholt, Thomas Veedfald, Anne Frølich, et al.

Experimental Hematology & Oncology|August 21, 2018

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myelomaHenrik Gregersen, Trung Do, Ida Bruun Kristensen, et al.

European Journal of Haematology|September 20, 2018

Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patientsLene Kongsgaard Nielsen, Tobias Wirenfeldt Klausen, Mary Jarden, et al.

Leukemia & Lymphoma|March 25, 2026

First-line immunochemotherapy for indolent lymphoma does not affect muscle volume: a post hoc analysis of 472 patients in long-term remissions from the GALLIUM studyJennifer Bøgh Jørgensen, Kim Vang Hansen, Lene Kongsgaard Nielsen, et al.

Leukemia|August 11, 2023

Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantationJakob Nordberg Nørgaard, Niels Abildgaard, Anna Lysén, et al.

Health and Quality of Life Outcomes|November 5, 2021

Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational studyMia Sommer, Lene Kongsgaard Nielsen, Lars Børty Nielsen, et al.

Archives of Gerontology and Geriatrics|January 21, 2021

Clinical presentation and mortality in hospitalized patients aged 80+ years with COVID-19-A retrospective cohort studyLinda Katharina Karlsson, Lasse Hjort Jakobsen, Louise Hollensberg, et al.

Pageof 3